NCT04305405 - PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 21, 2019

Primary Completion Date

September 12, 2022

Study Completion Date

September 12, 2022

Conditions

Severe Uncontrolled Asthma

Interventions

DRUG

Benralizumab

Dose will be stratified by body weight at screening: Patients will receive Dose 1 or Dose 2 of Benralizumab administered by SC injection at Day 0 and Weeks 4, 8, and 16, 24, 32, and 40.

Trial Locations (15)

15213

Research Site, Pittsburgh

32827

Research Site, Orlando

45229

Research Site, Cincinnati

68505

Research Site, Lincoln

75019

Research Site, Coppell

78251

Research Site, San Antonio

90078

Research Site, Los Angeles

811-1394

Research Site, Fukuoka

813-0017

Research Site, Fukuoka

721-8511

Research Site, Fukuyama-shi

500-8717

Research Site, Gifu

583-8588

Research Site, Habikino-shi

840-8571

Research Site, Saga

514-0125

Research Site, Tsu

765-8507

Research Site, Zentsuji-shi